Mammographic density is a potential predictive marker of pathological response after neoadjuvant chemotherapy in breast cancer
Abstract Background Our aim is to study if mammographic density (MD) prior to neoadjuvant chemotherapy is a predictive factor in accomplishing a pathological complete response (pCR) in neoadjuvant-treated breast cancer patients. Methods Data on all neoadjuvant treated breast cancer patients in South...
Main Authors: | Ida Skarping, Daniel Förnvik, Hanna Sartor, Uffe Heide-Jørgensen, Sophia Zackrisson, Signe Borgquist |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-12-01
|
Series: | BMC Cancer |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12885-019-6485-4 |
Similar Items
-
Mammographic density changes during neoadjuvant breast cancer treatment: NeoDense, a prospective study in Sweden
by: Ida Skarping, et al.
Published: (2020-10-01) -
Are baseline ultrasound and mammographic features associated with rates of pathological completes response in patients receiving neoadjuvant chemotherapy for breast cancer?
by: Sarah L. Savaridas, et al.
Published: (2019-10-01) -
Survival outcomes of locally advanced gastric cancer cases with pathological complete response received neoadjuvant chemotherapy
by: Qing Hu, et al.
Published: (2021-06-01) -
The implications of a pathological complete response of the primary tumour after neoadjuvant chemotherapy for breast cancer on axillary surgery
by: Mina M. G. Youssef, et al.
Published: (2021-02-01) -
Hormonal determinants of mammographic density and density change
by: Marike Gabrielson, et al.
Published: (2020-08-01)